Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD6-R52H9 | Rat | Rat B7-2 / CD86 Protein, His Tag |
|
|
|
CD6-H82F5 | Human | Biotinylated Human B7-2 / CD86 Protein, Fc,Avitag™, premium grade |
|
|
|
CD6-M52H0 | Mouse | Mouse B7-2 / CD86 Protein, His Tag (MALS verified) |
|
|
|
CD6-M5251 | Mouse | Mouse B7-2 / CD86 Protein, Fc Tag (MALS verified) |
|
|
|
CD6-C5254 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Fc Tag |
|
|
|
CD6-C52H5 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (MALS verified) |
|
|
|
CD6-H5223 | Human | Human B7-2 / CD86 Protein, His Tag (MALS verified) |
|
|
|
CD6-H5257 | Human | Human B7-2 / CD86 Protein, Fc Tag, premium grade |
|
|
Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag, premium grade (Cat. No. CD6-H82F5) to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).
Loaded Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag with an affinity constant of 11 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Belatacept | LEA29Y; LEA-029; BMS-224818; L104EA29YIg | Approved | Bristol-Myers Squibb Company | Nulojix | EU | Rejection of renal transplantation | Bristol-Myers Squibb Pharma Eeig | 2011-06-15 | Rejection of renal transplantation; Diabetes Mellitus, Type 1; Arthritis, Rheumatoid; Pancreatic neuroendocrine tumors (pNET); Proteinuria; Rejection of organ transplantation; Delayed Graft Function; Rejection in heart transplantation; Kidney Failure, Chronic | Details |
Abatacept | ONO-4164; BMS-188667; BMS-188667SC; ONO-4164SC | Approved | Bristol-Myers Squibb Company | Orencia | United States | Graft vs Host Disease | Bristol Myers Squibb Srlcompany | 2005-12-23 | Arthritis, Psoriatic; Arthritis; Arthralgia; Common Variable Immunodeficiency; Cardiovascular Diseases; Sjogren-Larsson Syndrome; Urticaria; Asthma; Colitis, Ulcerative; Nephrotic Syndrome; Lupus Erythematosus, Systemic; Takayasu Arteritis; Psoriasis; Anemia, Aplastic; Glomerulosclerosis, Focal Segmental; Mucopolysaccharidosis I; Polymyalgia Rheumatica; Multiple Sclerosis; Leukocyte-Adhesion Deficiency Syndrome; Uveitis; Granulomatous Disease, Chronic; Lymphohistiocytosis, Hemophagocytic; Scleroderma, Diffuse; Inflammation; Myocarditis; Eye Diseases; Muscular Diseases; Crohn Disease; Behcet Syndrome; Kostmann Syndrome; Anemia, Sickle Cell; Thrombasthenia; Vitiligo; Spondylitis, Ankylosing; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Granulomatosis with Polyangiitis; Wiskott-Aldrich Syndrome; Polymyositis; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Hematologic Diseases; Alopecia Areata; Giant Cell Arteritis; Myositis; Dermatomyositis; Immunoglobulin G | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CTLA-4/FasL fusion protein (KAHR Medical) | KAHR-102 | Kahr Medical | Details | ||
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) | Phase 1 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid | Details | |
ORCA-010 | ORCA-010 | Phase 2 Clinical | Orca Therapeutics Bv | Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.